financetom
Business
financetom
/
Business
/
Cogent Biosciences posts wider Q3 loss as costs rise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cogent Biosciences posts wider Q3 loss as costs rise
Nov 3, 2025 6:30 AM

Overview

* Cogent Biosciences ( COGT ) reports Q3 net loss of $80.9 mln, up from $70.6 mln in 2024

* Cash position of $390.9 mln expected to fund operations through 2027

* Upcoming PEAK and APEX trial results expected in Nov and Dec 2025

Outlook

* Cogent plans to announce PEAK trial results in November 2025

* Company expects APEX trial results in December 2025

* Cogent aims to submit NDA for bezuclastinib by year-end 2025

Result Drivers

* R&D EXPENSES - Increased R&D expenses due to ongoing clinical trials and preclinical programs

* CASH POSITION - Strong cash position expected to fund operations through 2027

* CLINICAL PROGRESS - Significant progress with upcoming trial results and regulatory submissions

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$80.93

Income mln

Q3 -$83.35

Income mln

from

Operatio

ns

Q3 $83.35

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Cogent Biosciences Inc ( COGT ) is $20.50, about 20.5% above its October 31 closing price of $16.30

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved